Serum levels of tissue inhibitor of metalloproteinase-1 and 2 in patients with eosinophilic fasciitis

British Journal of Dermatology

Volumn 151, Issue 2, 2004, Pages 407-412

  Jinnin, M ^a   Ihn, H ^a   Yamane, K ^a   Asano, Y ^a   Yazawa, N ^a   Tamaki, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Eosinophilic fasciitis; Matrix metalloproteinase; Systemic sclerosis

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN G; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIC FASCIITIS; FASCIA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL;

ADRENAL CORTEX HORMONES; EOSINOPHILIA; FASCIITIS; HUMANS; IMMUNOHISTOCHEMISTRY; SKIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 4544259837     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06062.x     Document Type: Article

References (34)

1. Shulman LE. Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol 1974; 1 (Suppl. 1): 46.
2. Kirschstein M, Helmchen U, Jensen R et al. Kidney involvement in a 17-year-old boy with eosinophilic fasciitis. Clin Nephrol 1999; 52: 183-7.
3. Doyle JA. Eosinophilic fasciitis: extracutaneous manifestations and associations. Cutis 1984; 34: 259-61.
4. Seibold JR, Rodnan GP, Medsger TA, Winkelstein A. Circulating immune complexes in eosinophilic fasciitis. Arthritis Rheum 1982; 25: 1180-5.
5. Janin A, Socie G, Devergie A et al. Fasciitis in chronic graft-versus-host disease - a clinicopathologic study of 14 cases. Ann Intern Med 1994; 120: 993-8.
6. Doyle JA, Ginsberg WW. Eosinophilic fasciitis. Med Clin North Am 1989; 73: 1157-66.
7. Viallard JF, Taupin JL, Ranchin V et al. Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis. J Rheumatol 2001; 28: 75-80.
8. Murawaki Y, Ikuta Y, Kawasaki H. Clinical usefulness of serum inhibitor of metalloproteinases (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1. Clin Chim Acta 1999; 281: 109-20.
9. Hayakawa T, Yamashita K, Tanzawa K et al. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. FEBS Lett 1992; 29: 32-4.
10. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994; 107: 2373-9.
11. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Br J Surg 1997; 84: 160-6.
12. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-22.
13. Cawston TE. Protein inhibitors of metallo-proteinases. In: Proteinase Inhibitors (Barrett AJ, Salveson G, eds). Amsterdam: Elsevier, 1986: 589-610.
14. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2). J Biol Chem 1989; 264: 17374-8.
15. Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor β receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001; 44: 731-4.
16. Hofmann UB, Westphal JR, van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000; 115: 337-44.
17. Airola K, Karonen T, Vaalamo M et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999; 80: 733-43.
18. Krengel S, Alexander M, Brinckmann J, Tronnier M. MMP-2, TIMP-2 and MT1-MMP are differentially expressed in lesional skin of melanocytic nevi and their expression is modulated by UVB-light. J Cutan Pathol 2002; 29: 390-6.
19. Bergstrom M, Lefvert AK. An automated turbidimetric immunoassay for plasma proteins. Scand J Clin Lab Invest 1980; 40: 637-40.
20. Kodama S, Iwata K, Iwata H et al. Rapid one-step sandwich enzyme immnoassay for tissue inhibitor of metalloproteinases: an application for rheumatoid arthritis serum and plasma. J Immunol Methods 1990; 127: 103-8.
21. Kikuchi K, Kadono T, Furue M, Tamaki K. Tissue inhibitor of metalloproteinase (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol 1997; 108: 281-4.
22. Kikuchi K, Kubo M, Sato S et al. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol 1995; 33: 973-8.
23. Kubo M, Kikuchi K, Fujimoto M, Tamaki K. Serum concentrations of carboxyterminal propeptide of type 1 procollagen and tissue inhibitor of metalloproteinase 1 in patients with dermatomyositis. Arch Dermatol Res 1998; 290: 253-7.
24. Yazawa N, Kikuchi K, Ihn H et al. Serum levels of tissue inhibitor of metalloproteinases-2 (TIMP-2) in patients with systemic sclerosis. J Am Acad Dermatol 2000; 42: 70-5.
25. Mattila L, Airola K, Ahonen M et al. Activation of tissue inhibitor of metalloproteinases-3 mRNA expression in scleroderma skin fibroblasts. J Invest Dermatol 1998; 110: 416-21.
26. Doyle JA, Connolly SM, Winkelmann RK. Cutaneous and subcutaneous inflammatory sclerosis syndromes. Arch Dermatol 1982; 118: 886-90.
27. van den Burgh V, Tricot G, Fonteyn G et al. Diffuse fasciitis after bone marrow transplantation. Am J Med 1987; 83: 139-43.
28. Fleischmajer R, Jacotot AB, Shore S, Binnick SA. Scleroderma, eosinophilia and diffuse fasciitis. Arch Dermatol 1978; 114: 1320-5.
29. American Rheumatism Association. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Bull Rheum Dis 1981; 31: 1-6.
30. Doyle JA, Connolly SM, Hoagland HC. Hematologic disease in scleroderma syndromes. Acta Derm Venereol (Stockh) 1985; 65: 521-5.
31. Yoshihara Y, Nakamura H, Obata K et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000; 59: 455-61.
32. Young-Min SA, Beeton C, Laughton R et al. Serum TIMP-1. TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Ann Rheum Dis 2001; 60: 846-51.
33. Falanga V, Medsger TA. Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. J Am Acad Dermatol 1987; 17: 648-56.
34. Fujimoto M, Sato S, Ihn H et al. Serum aldolase level is a useful indicator of disease activity in eosinophilic fasciitis. J Rheumatol 1995; 22: 563-5.